This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:


trusted source


Macaque trials offer hope in pneumonia vaccine development

Macaque trials offer hope in pneumonia vaccine development
Left: Control group (non-vaccine-treated); the red arrow shows the area where pneumonia developed. Right: Vaccine-treated group comprising cynomolgus macaques or crab-eating macaques; suppression of infection was observed. Credit: Department of Immunology and Genomics at the Graduate School of Medicine, Osaka Metropolitan University

The global impact of the coronavirus pandemic has ignited a renewed focus on emerging and re-emerging infectious diseases. Researchers at Osaka Metropolitan University are making great strides in combating pneumococcal pneumonia, one of the leading causes of respiratory deaths worldwide.

Despite the existence of vaccines against pneumococcal infections such as , sinusitis, and meningitis, the prevalence of pneumococcal remains high. Currently, around 100 new serotypes of Streptococcus pneumoniae have been identified, and the increase in caused by serotypes not covered by the has become a concern. This situation underscores the need for a more versatile vaccine.

Building on their previous success in mucosal responses in 2019, in which they developed a mucosal vaccine that can induce antigen-specific mucosal immune responses, mainly immunoglobulin A (IgA), on the target mucosal surface, a research team led by Professor Satoshi Uematsu and Associate Professor Kosuke Fujimoto from the Department of Immunology and Genomics at the Graduate School of Medicine, Osaka Metropolitan University, has this time set out to bridge the gap in pneumococcal pneumonia vaccination efficacy.

Their findings were published in Inflammation and Regeneration.

To successfully develop a novel pneumococcal vaccine, the research team combined its proprietary mucosal vaccine technology with pneumococcal surface proteins that can cover a wide range of serotypes. Experiments conducted on mice and macaques have demonstrated the vaccine's efficacy in suppressing pneumococcal pneumonia in the target animal groups.

"This research has succeeded in developing a vaccine formulation that can potentially be used in humans, which will advance the development of this vaccine for clinical applications," said Professor Fujimoto. "This next-generation vaccine technology is expected to contribute to the treatment of in the future."

More information: Chieko Yokota et al, Prime-boost-type PspA3 + 2 mucosal vaccine protects cynomolgus macaques from intratracheal challenge with pneumococci, Inflammation and Regeneration (2023). DOI: 10.1186/s41232-023-00305-2

Citation: Macaque trials offer hope in pneumonia vaccine development (2023, November 28) retrieved 4 March 2024 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

National study suggests new vaccine is needed to prevent childhood pneumonia


Feedback to editors